Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Addition of Fulvestrant to Erlotinib in NSCLC
NCT00592007Phase 2Terminated
- Start
- Sep 2007
- Primary completion
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fulvestrant in non-small cell lung cancer (NSCLC). Started Sep 2007; status: terminated.
02
Drugs
fulvestrant
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00592007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00592007.